New drug aims to stop transplant complications in blood cancer patients

NCT ID NCT07349771

First seen Jan 20, 2026 · Last updated May 02, 2026 · Updated 19 times

Summary

This study tests whether adding the drug axatilimab to standard care can prevent graft-versus-host disease (GVHD) in 72 adults with blood cancer who receive a stem cell transplant from a matched donor. GVHD occurs when donor cells attack the patient's body, causing symptoms like skin rash, dry eyes, and mouth sores. Axatilimab is a monoclonal antibody that targets immune signals to reduce this risk. The main goal is to see if patients survive one year without severe GVHD needing strong immune-suppressing drugs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, 85259, United States

    Contact Phone: •••-•••-••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic in Florida

    Jacksonville, Florida, 32224-9980, United States

    Contact Phone: •••-•••-••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.